FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)pyridin-4-yloxy]-1H-benzimidazol-2-yl}(4-trifluoromethylphenyl)amine salt. Also, the invention refers to a pharmaceutical composition based on the declared salt, to a method for preparing said pharmaceutical composition and to a method of treating cancer and/or angiogenesis based on the use of the declared salt.
EFFECT: there are prepared new {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)pyridine-4-yloxy]-1H-benzimidazol-2-yl}(4-trifluoromethylphenyl)amine salts showing effective biological properties.
42 cl, 12 dwg, 10 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BENZIMIDAZOLYLPYRIDYL ESTER COMPOUNDS | 2007 |
|
RU2452469C2 |
| COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING NILOTINIB OR ITS SALTS | 2007 |
|
RU2469707C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2383545C2 |
| PHARMACEUTICAL COMPOSITION FOR USING IN THERAPY OF MALIGNANT NEOPLASM COMPRISING COMBINATION OF BISPHOSPHONATE, COX-2 INHIBITOR AND TAXOL | 2002 |
|
RU2317819C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING AMINOPYRAZOLE DERIVATIVE | 2014 |
|
RU2684618C2 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
| COMBINATION OF PYRIMIDYLAMINOBENZAMIDE AND mTOR KINASE INHIBITOR | 2006 |
|
RU2443418C2 |
| CARBOXAMIDE DERIVATIVES OF ISOXAZOLINE, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING INFLAMMATORY DISEASES | 2018 |
|
RU2704967C1 |
| DERIVATIVES OF BETA-CARBOLINE POSSESSING EFFECT OF PHOSPHODIESTERASE INHIBITORS, PHARMACEUTICAL COMPOSITION (VARIANTS), METHOD FOR ITS PREPARING, METHOD FOR INHIBITION OF PHOSPHODIESTERASE EFFECT (VARIANTS) AND METHOD FOR INCREASING CGMP CONCENTRATION | 2001 |
|
RU2271358C2 |
